Combining intraoperative XXXX wafers and Stupp regimen in multimodal first-line treatment of @entity463 .

@entity1 @entity3600 @entity204 @entity463
UNASSIGNED: Background. The study investigated if intraoperative use of @entity3600 wafers, particularly in combination with Stupp regimen, is a viable and safe first-line treatment option of @entity463 . Methods. Eighty-three consecutive adult @entity1 (50 @entity1 ; mean age 60 years) with newly diagnosed supratentorial @entity463 that underwent surgical resection with intraoperative @entity3600 wafers implantation (n = 7.1    1.7) were retrospectively studied. Results. The median overall survival (OS) was 15.8 months with 56 @entity1 dying over the course of the study. There was no significant association between the number of implanted @entity3600 wafers and complication rates (four surgical site infections, one @entity204 ). The OS was significantly longer in Stupp regimen @entity1 (19.5 months) as compared with @entity1 with other postoperative treatments (13 months; p = 0.002). In addition @entity1 with eight or more implanted @entity3600 wafers survived longer (24.5 months) than @entity1 with seven or less implanted wafers (13 months; p = 0.021). Finally, regardless of the number of @entity3600 wafers, median OS was significantly longer in @entity1 with a subtotal or total resection (21.5 months) than in @entity1 with a partial resection (13 months; p = 0.011). Conclusions. The intraoperative use of @entity3600 wafers in combination with Stupp regimen is a viable first-line treatment option of @entity463 . The prognostic value of this treatment association should be evaluated in a multicenter trial, ideally in a randomized and placebo-controlled one.
